XBIOTECH INC (XBIT) Stock Fundamental Analysis

NASDAQ:XBIT • CA98400H1029

2.26 USD
-0.09 (-3.83%)
Last: Feb 27, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XBIT. XBIT was compared to 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for XBIT as it has an excellent financial health rating, but there are worries on the profitability. XBIT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year XBIT has reported negative net income.
  • In the past year XBIT has reported a negative cash flow from operations.
  • In the past 5 years XBIT always reported negative net income.
  • In the past 5 years XBIT reported 4 times negative operating cash flow.
XBIT Yearly Net Income VS EBIT VS OCF VS FCFXBIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • XBIT has a better Return On Assets (-17.19%) than 77.78% of its industry peers.
  • XBIT's Return On Equity of -17.74% is amongst the best of the industry. XBIT outperforms 85.06% of its industry peers.
Industry RankSector Rank
ROA -17.19%
ROE -17.74%
ROIC N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
XBIT Yearly ROA, ROE, ROICXBIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • XBIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIT Yearly Profit, Operating, Gross MarginsXBIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for XBIT remains at a similar level compared to 1 year ago.
  • XBIT has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for XBIT is higher compared to a year ago.
XBIT Yearly Shares OutstandingXBIT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XBIT Yearly Total Debt VS Total AssetsXBIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • XBIT has an Altman-Z score of 7.20. This indicates that XBIT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.20, XBIT is in the better half of the industry, outperforming 77.01% of the companies in the same industry.
  • XBIT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.2
ROIC/WACCN/A
WACCN/A
XBIT Yearly LT Debt VS Equity VS FCFXBIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 41.78 indicates that XBIT has no problem at all paying its short term obligations.
  • XBIT has a Current ratio of 41.78. This is amongst the best in the industry. XBIT outperforms 99.04% of its industry peers.
  • A Quick Ratio of 41.78 indicates that XBIT has no problem at all paying its short term obligations.
  • XBIT's Quick ratio of 41.78 is amongst the best of the industry. XBIT outperforms 99.04% of its industry peers.
Industry RankSector Rank
Current Ratio 41.78
Quick Ratio 41.78
XBIT Yearly Current Assets VS Current LiabilitesXBIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 9.38% over the past year.
EPS 1Y (TTM)9.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XBIT Yearly Revenue VS EstimatesXBIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 10M 20M 30M 40M
XBIT Yearly EPS VS EstimatesXBIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XBIT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIT Price Earnings VS Forward Price EarningsXBIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIT Per share dataXBIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • XBIT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XBIOTECH INC

NASDAQ:XBIT (2/27/2026, 8:00:02 PM)

2.26

-0.09 (-3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners9.77%
Inst Owner Change-20.81%
Ins Owners36.61%
Ins Owner Change0%
Market Cap68.91M
Revenue(TTM)N/A
Net Income(TTM)-29.65M
Analysts82.86
Price TargetN/A
Short Float %0.59%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.19%
ROE -17.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 41.78
Quick Ratio 41.78
Altman-Z 7.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.36%
Cap/Depr(5y)83.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.91%
OCF growth 3YN/A
OCF growth 5YN/A

XBIOTECH INC / XBIT FAQ

Can you provide the ChartMill fundamental rating for XBIOTECH INC?

ChartMill assigns a fundamental rating of 3 / 10 to XBIT.


Can you provide the valuation status for XBIOTECH INC?

ChartMill assigns a valuation rating of 0 / 10 to XBIOTECH INC (XBIT). This can be considered as Overvalued.


How profitable is XBIOTECH INC (XBIT) stock?

XBIOTECH INC (XBIT) has a profitability rating of 1 / 10.


How financially healthy is XBIOTECH INC?

The financial health rating of XBIOTECH INC (XBIT) is 8 / 10.